Stocktwits30d agobullish
BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home UseThe decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
330last 24h
2137last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
Investing.com30d agobullish
Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key dataInvesting.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.
Barrons.com30d agobullish
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study DetailsBiogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.